Severe Persistent Eczema in a Recipient of the Gam-COVID-Vac vaccine

Abstract

Since the beginning of the COVID-19 pandemic, efforts have been made to design safe and effective vaccines against SARS-CoV-2. Numerous vaccines have been designed and tested in limited clinical trials in various countries. Among them, the Sputnik V vaccine has shown a relatively safe profile and, to our knowledge, has no associated major side effects. We describe the case of a 40-year-old female healthcare worker who developed severe persistent eczematous lesions on the second day after she received the first dose of the Sputnik vaccine. The eczematous lesions were refractory to an antihistamine and persisted at the 1 month follow-up. Severe persistent eczematous lesions should be viewed as a potential side effect of vaccination with the Sputnik V vaccine. Moreover, a severe allergic reaction to a COVID-2019 vaccine may indicate the vaccine is ineffective in the recipient.

Evaluation of short-term adverse events of COVID-19 vaccines: An observational study

“…In a cross-sectional study, 1 case of urticaria and 2 cases of hot flashes were reported after receiving the Sputnik vaccine without recording the duration of AEs. [18] Studies have shown that mRNA-based vaccines can cause allergic reactions and anaphylaxis. [19] One of the materials used as an adjuvant in vaccines is polyethylene glycol (PEG).…”

Sputnik V vaccine-related complications and its impression on inflammatory biomarkers in healthcare providers

“…Although the most common complication of this vaccine was a mild flu-like condition, there were some reports demonstrating severe complications after Sputnik-v vaccine jab in Iran. For instance, Guillain-Barre Syndrome (GBS), Bell’s palsy, myocarditis, reactivation of latent herpes zoster, and severe persistent eczema have been reported in Iranian people following rAd26 and rAd5 vector-based COVID-19 vaccine administration [ [14] , [15] , [16] , [17] ].…”